Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue OxyContin Abuse-Resistant Pill Will Need 4-5 Years To Complete Trials

Executive Summary

Purdue expects clinical trials of abuse-resistant OxyContin formulated with the opioid antagonist naltrexone will take four to five years to complete, after determining that a combination product with naloxone will likely not be feasible

You may also be interested in...



Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval

The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch

Subutex/Suboxone Prescriber Registration Efforts Ramping Up After Approval

The Substance Abuse & Mental Health Services Administration is working to register physicians to prescribe Schering-Plough/Reckitt Benckiser's opioid addiction treatment therapies Subutex and Suboxone in advance of the products' launch

Purdue OxyContin Marketing Strategy To Be Topic Of GAO Investigation

Purdue Pharma's marketing strategies for OxyContin will be the topic of a Government Accounting Office report requested by House Appropriations/Commerce, Justice, State & Judiciary Subcommittee Chairman Frank Wolf (R-Va.)

Related Content

UsernamePublicRestriction

Register

PS040061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel